caplacizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5308 915810-67-2

Description:

MoleculeDescription

Synonyms:

  • caplacizumab
  • ALX-0081
  • ALX-0681
  • calibvi
  • caplacizumab-yhdp
In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 30, 2018 EMA ABLYNX NV
Feb. 6, 2019 FDA ABLYNX NV
Sept. 26, 2022 PMDA SANOFI K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 213.56 49.72 24 591 103 63488304
ADAMTS13 activity abnormal 179.50 49.72 17 598 0 63488407
Product use in unapproved indication 114.90 49.72 48 567 179032 63309375
Platelet count decreased 77.05 49.72 32 583 116090 63372317

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity abnormal 98.60 49.42 9 220 0 34956702
ADAMTS13 activity decreased 96.85 49.42 11 218 84 34956618

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 260.44 51.65 30 763 162 79743433
ADAMTS13 activity abnormal 242.26 51.65 23 770 0 79743595
Product use in unapproved indication 152.08 51.65 65 728 250294 79493301
Platelet count decreased 71.91 51.65 36 757 194628 79548967

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AX07 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Other antithrombotic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Thrombotic thrombocytopenic purpura indication 78129009 DOID:10772




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
von Willebrand factor Unclassified ANTIBODY BINDING Kd 8.51 IUPHAR DRUG LABEL

External reference:

IDSource
2R27AB6766 UNII
C3713057 UMLSCUI
CHEMBL2109624 ChEMBL_ID
DB06081 DRUGBANK_ID
D11160 KEGG_DRUG
9511 INN_ID
9123 IUPHAR_LIGAND_ID
017896 NDDF
784411004 SNOMEDCT_US
789447000 SNOMEDCT_US
4038197 VANDF
4038198 VANDF
2110604 RXNORM
36265 MMSL
36266 MMSL
d09171 MMSL
C585343 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None